Chemical Development

New Brunswick, United States

Chemical Development

New Brunswick, United States

Time filter

Source Type

News Article | May 9, 2017
Site: www.prnewswire.co.uk

Non-GAAP net income, non-GAAP diluted EPS and adjusted EBITDA are non-GAAP financial measures. For a discussion of these measures and reconciliations to U.S. GAAP measures, see "Non-GAAP Financial Measures" and Tables 1, 2 and 3. "We delivered an excellent first quarter, driven by 56 percent growth in contract revenue, 7 percent on an organic basis, including double digit organic growth in our Discovery, Development and Analytical Services (DDS) and Active Pharmaceutical Ingredient (API) businesses," said William S. Marth, AMRI's president and chief executive officer. "GAAP income from operations increased $6 million, a 150% increase quarter over quarter,   and adjusted EBITDA increased $11 million, an 83% increase quarter over quarter, illustrating strong and efficient execution and leverage across our operations. We are confident that these trends will continue through the year and are maintaining our outlook for 2017, which includes 28% growth of contract revenue, 7% growth of organic contract revenue, and double digit earnings growth at the midpoint." Total revenue for the first quarter of 2017 was $163.8 million, an increase of 55%, compared to total revenue of $105.6 million reported in the first quarter of 2016. Total contract revenue for the first quarter of 2017 was $160.2 million, an increase of 56% compared to contract revenue of $102.8 million reported in the first quarter of 2016, and organic contract revenue increased 7%. Contract gross margin was 23% for the first quarter of 2017, consistent with contract gross margin for the first quarter of 2016. Non-GAAP contract gross margin was 27% in the first quarter of 2017, consistent with the first quarter of 2016 and reflects increased gross margin within our Drug Product (DP) business, offset by the addition of Euticals' Fine Chemicals (FC) and API businesses. Recurring royalty revenue in the first quarter of 2017 was $3.6 million, an increase of 31% from $2.7 million in the first quarter of 2016 due primarily to the addition of royalties resulting from our collaboration partner's sales of nitroprusside. Selling, general and administrative (SG&A) expense in the first quarter of 2017 was $33.4 million, up 36% from $24.6 million in the first quarter of 2016. Non-GAAP SG&A expense in the first quarter of 2017 was $27.0 million, up 47% from $18.4 million in the first quarter of 2016, due largely to additional SG&A from the Euticals' acquisition and investments we have made in key support functions. Net loss was $(10.7) million, or $(0.25) per basic and diluted share, in the first quarter of 2017, compared to $(10.1) million, or $(0.29) per basic and diluted share for the first quarter of 2016. Non-GAAP net income in the first quarter was $5.7 million, or $0.13 per diluted share, compared to $2.4 million, or $0.07 per diluted share, for the first quarter of 2016. Adjusted EBITDA in the first quarter of 2017 was $24.0 million, an increase of $11.0 million or 83%, compared to the first quarter of 2016. At March 31, 2017, AMRI had cash and cash equivalents of $35.2 million, compared to $52.0 million at December 31, 2016. During the first quarter of 2017, we used cash of $6.4 million in operating activities primarily due to the timing of payments attributable to severance, employee compensation and benefits and payments to vendors that were primarily incurred and accrued as of December 31, 2016, as well as payments associated with increased inventory levels during the period. These outflows were partially offset by collections from customers during the period. We used cash of $4.1 million in investing activities, primarily attributable to $3.9 million of capital expenditures, and we used cash of $7.2 million in financing activities, primarily related to the principal payments of long-term debt of $4.0 million and net repayments on short-term borrowings of $2.0 million. API contract revenue for the first quarter of 2017 increased 90% compared to the first quarter of 2016, due to $43.4 million of incremental revenue from our Euticals' API business and organic growth. API contract gross margin for the first quarter of 2017 decreased 3 percentage points compared to the first quarter of 2016, primarily due to gross margins attributable to Euticals as compared to our legacy API business. API non-GAAP contract gross margin for the first quarter of 2017 decreased 4 percentage points from the first quarter of 2016 also as a result of lower margins of Euticals' API business as compared to our legacy API business. DDS contract revenue for the first quarter of 2017 increased 24% compared to the first quarter of 2016, due primarily to strong growth in Discovery and Chemical Development. DDS contract gross margin increased 1 percentage point in the first quarter of 2017 as compared to the first quarter of 2016. DDS non-GAAP contract gross margin increased 1 percentage point to 30% in the first quarter of 2017, driven by higher discovery services and chemical development margins. DP contract revenue for the first quarter of 2017 decreased 10% compared to the first quarter of 2016, primarily due to timing of shipments and planned site maintenance activities, partially offset by higher collaboration arrangement revenue. DP contract gross margin and non-GAAP contract gross margin for the first quarter 2017 both increased 9 percentage points compared to the first quarter of 2016, primarily driven by the strong operational performance at the Albuquerque, NM facility. DP royalty revenue in the first quarter of 2017, reflects the addition of royalties resulting from our collaboration partner's sales of nitroprusside, which began in the fourth quarter of 2016. FC is a new reporting segment for AMRI resulting from the acquisition of Euticals in July 2016. Consequently, there are no comparable amounts for the first quarter of 2016. AMRI's guidance takes into account a number of factors, including expected financial results for 2017, anticipated tax rates, foreign currency fluctuations and shares outstanding. AMRI's estimates for full year 2017 are consistent with estimates previously provided on February 21, 2017: AMRI will host a conference call and webcast today at 8:30 a.m. ET to discuss first quarter 2017 results, as well as guidance for 2017. The conference call can be accessed by dialing (866) 208-5728 (domestic calls) or (224) 633-1279 (international calls) at 8:20 a.m. ET and entering passcode 7657377. The webcast and supplementing slides can be accessed on the company's website at www.amriglobal.com. A replay of the conference call can be accessed for 24 hours at (855) 859-2056 (domestic calls) or (404) 537-3406 (international calls) and entering passcode 75749093. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at http://ir.amriglobal.com. About AMRI Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals (FC). For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal). Forward-looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, all of the estimates under "Financial Outlook" and statements regarding, among other things, the performance of the Company's previously acquired businesses, the strength of the Company's commercial operations and prospects, projections regarding future revenues and financial performance, and the Company's momentum and long-term growth. The words "outlook", "guidance", "anticipates", "believes", "expects", "may", "plans", "predicts", "will", "potential", "goal" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. The Company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the Company may not be able to predict and may not be within the Company's control. Factors that could cause such differences include, but are not limited to, changes in customers' spending and demand and the trends in pharmaceutical and biotechnology companies' outsourcing of manufacturing services and research and development; the Company's ability to provide quality and timely services and to compete with other companies providing similar services; the Company's ability to comply with strict regulatory requirements; the Company's ability to successfully integrate past and future acquisitions and to realize the expected benefits of each; disruptions in the Company's ability to source raw materials; a change in the Company's relationships with its largest customers; the Company's ability to service its indebtedness; the Company's ability to protect its technology and proprietary information and the confidential information of its customers; the Company's ability to develop products of commercial value under its collaboration arrangements; the risk of patent infringement and other litigation; as well as those risks discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission (SEC) on March 16, 2017, subsequent Quarterly Reports filed with the SEC and the Company's other SEC filings. The financial guidance offered by senior management with respect to 2017 represents a point-in-time estimate and is based on information as of the date of this press release. Senior management has made numerous assumptions in providing this guidance which, while believed to be reasonable, may not prove to be accurate. Numerous factors, including those noted above, may cause actual results to differ materially from the guidance provided. The Company expressly disclaims any current intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements contained in this press release. Non-GAAP Financial Measures To supplement our financial results prepared in accordance with U.S. GAAP, we have presented non-GAAP measures of contract gross profit, contract gross margin, gross profit, gross margin, SG&A, net income, and earnings per diluted share, adjusted to exclude certain charges (and gains when applicable) that relate to specific events or transactions, such as impairment charges, restructuring charges, executive transition costs, business acquisition costs, realized and unrealized gains and losses on foreign currency transactions related to business acquisitions, and ERP implementation costs. Management typically excludes these amounts when evaluating our operating performance and believes that the resulting non-GAAP measures provide investors with a consistent basis for comparison across periods and, therefore, are useful to investors in assessing our operating performance. Our U.S. GAAP measures are also adjusted to exclude certain non-cash charges (and gains when applicable) such as non-cash debt interest and amortization charges, share-based compensation expense, acquisition accounting inventory adjustments, and acquisition accounting depreciation and amortization for the periods presented for 2017 and 2016. Management typically excludes the amounts described above when evaluating our operating performance and believes that the resulting non-GAAP measures are useful to investors in assessing our operating performance. We have also presented the non-GAAP measure of adjusted EBITDA, which in addition to the items excluded above, further excludes the impact of interest income and expense, depreciation and amortization expense, and income tax expense or benefit. We believe presentation of our non-GAAP measures enhances an overall understanding of our historical financial performance because we believe these measures are an indication of the performance of our base business. Management uses these non-GAAP measures as a basis for evaluating our financial performance as well as for budgeting and forecasting of future periods. For these reasons, we believe they can be useful to investors. The presentation of this additional information should not be considered in isolation or as a substitute for the related GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are set forth in Tables 1-3. A reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures has been included in Table 4. A reconciliation of organic revenue financial measures to the most directly comparable GAAP financial measures has been included in Table 5. Table 1: Reconciliation of three months ended March 31, 2017 and 2016 contract gross profit and contract gross margin to the non-GAAP financial measures of contract gross profit and non-GAAP contract gross margin. Table 2: Reconciliation of select financial measures to non-GAAP financial measures for the three months ended March 31, 2017 and 2016: Table 3: Reconciliation of the three months ended March 31, 2017 and 2016 net loss to the non-GAAP financial measure of adjusted EBITDA: Table 4:  Reconciliation of forward-looking GAAP financial measures to forward looking non-GAAP financial measures: When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis as that would require estimates for various reconciling items that would be difficult to predict with reasonable accuracy.  For example, it is difficult for the Company to anticipate the need for, or magnitude of, any presently unforeseen one-time restructuring expense or business acquisition costs.  As a result, the Company has prepared the below reconciliation using estimates of reconciling items that are currently expected to be excluded from the non-GAAP financial measures in future periods.  The Company is unable to include all reconciling items at this time without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to variability, complexity and limited visibility to events or conditions in future periods. Table 5: Reconciliation of non-GAAP organic revenue for the three months ended March 31, 2017 and 2016:


News Article | May 9, 2017
Site: www.prnewswire.com

Non-GAAP net income, non-GAAP diluted EPS and adjusted EBITDA are non-GAAP financial measures. For a discussion of these measures and reconciliations to U.S. GAAP measures, see "Non-GAAP Financial Measures" and Tables 1, 2 and 3. "We delivered an excellent first quarter, driven by 56 percent growth in contract revenue, 7 percent on an organic basis, including double digit organic growth in our Discovery, Development and Analytical Services (DDS) and Active Pharmaceutical Ingredient (API) businesses," said William S. Marth, AMRI's president and chief executive officer. "GAAP income from operations increased $6 million, a 150% increase quarter over quarter,   and adjusted EBITDA increased $11 million, an 83% increase quarter over quarter, illustrating strong and efficient execution and leverage across our operations. We are confident that these trends will continue through the year and are maintaining our outlook for 2017, which includes 28% growth of contract revenue, 7% growth of organic contract revenue, and double digit earnings growth at the midpoint." Total revenue for the first quarter of 2017 was $163.8 million, an increase of 55%, compared to total revenue of $105.6 million reported in the first quarter of 2016. Total contract revenue for the first quarter of 2017 was $160.2 million, an increase of 56% compared to contract revenue of $102.8 million reported in the first quarter of 2016, and organic contract revenue increased 7%. Contract gross margin was 23% for the first quarter of 2017, consistent with contract gross margin for the first quarter of 2016. Non-GAAP contract gross margin was 27% in the first quarter of 2017, consistent with the first quarter of 2016 and reflects increased gross margin within our Drug Product (DP) business, offset by the addition of Euticals' Fine Chemicals (FC) and API businesses. Recurring royalty revenue in the first quarter of 2017 was $3.6 million, an increase of 31% from $2.7 million in the first quarter of 2016 due primarily to the addition of royalties resulting from our collaboration partner's sales of nitroprusside. Selling, general and administrative (SG&A) expense in the first quarter of 2017 was $33.4 million, up 36% from $24.6 million in the first quarter of 2016. Non-GAAP SG&A expense in the first quarter of 2017 was $27.0 million, up 47% from $18.4 million in the first quarter of 2016, due largely to additional SG&A from the Euticals' acquisition and investments we have made in key support functions. Net loss was $(10.7) million, or $(0.25) per basic and diluted share, in the first quarter of 2017, compared to $(10.1) million, or $(0.29) per basic and diluted share for the first quarter of 2016. Non-GAAP net income in the first quarter was $5.7 million, or $0.13 per diluted share, compared to $2.4 million, or $0.07 per diluted share, for the first quarter of 2016. Adjusted EBITDA in the first quarter of 2017 was $24.0 million, an increase of $11.0 million or 83%, compared to the first quarter of 2016. At March 31, 2017, AMRI had cash and cash equivalents of $35.2 million, compared to $52.0 million at December 31, 2016. During the first quarter of 2017, we used cash of $6.4 million in operating activities primarily due to the timing of payments attributable to severance, employee compensation and benefits and payments to vendors that were primarily incurred and accrued as of December 31, 2016, as well as payments associated with increased inventory levels during the period. These outflows were partially offset by collections from customers during the period. We used cash of $4.1 million in investing activities, primarily attributable to $3.9 million of capital expenditures, and we used cash of $7.2 million in financing activities, primarily related to the principal payments of long-term debt of $4.0 million and net repayments on short-term borrowings of $2.0 million. API contract revenue for the first quarter of 2017 increased 90% compared to the first quarter of 2016, due to $43.4 million of incremental revenue from our Euticals' API business and organic growth. API contract gross margin for the first quarter of 2017 decreased 3 percentage points compared to the first quarter of 2016, primarily due to gross margins attributable to Euticals as compared to our legacy API business. API non-GAAP contract gross margin for the first quarter of 2017 decreased 4 percentage points from the first quarter of 2016 also as a result of lower margins of Euticals' API business as compared to our legacy API business. DDS contract revenue for the first quarter of 2017 increased 24% compared to the first quarter of 2016, due primarily to strong growth in Discovery and Chemical Development. DDS contract gross margin increased 1 percentage point in the first quarter of 2017 as compared to the first quarter of 2016. DDS non-GAAP contract gross margin increased 1 percentage point to 30% in the first quarter of 2017, driven by higher discovery services and chemical development margins. DP contract revenue for the first quarter of 2017 decreased 10% compared to the first quarter of 2016, primarily due to timing of shipments and planned site maintenance activities, partially offset by higher collaboration arrangement revenue. DP contract gross margin and non-GAAP contract gross margin for the first quarter 2017 both increased 9 percentage points compared to the first quarter of 2016, primarily driven by the strong operational performance at the Albuquerque, NM facility. DP royalty revenue in the first quarter of 2017, reflects the addition of royalties resulting from our collaboration partner's sales of nitroprusside, which began in the fourth quarter of 2016. FC is a new reporting segment for AMRI resulting from the acquisition of Euticals in July 2016. Consequently, there are no comparable amounts for the first quarter of 2016. AMRI's guidance takes into account a number of factors, including expected financial results for 2017, anticipated tax rates, foreign currency fluctuations and shares outstanding. AMRI's estimates for full year 2017 are consistent with estimates previously provided on February 21, 2017: AMRI will host a conference call and webcast today at 8:30 a.m. ET to discuss first quarter 2017 results, as well as guidance for 2017. The conference call can be accessed by dialing (866) 208-5728 (domestic calls) or (224) 633-1279 (international calls) at 8:20 a.m. ET and entering passcode 7657377. The webcast and supplementing slides can be accessed on the company's website at www.amriglobal.com. A replay of the conference call can be accessed for 24 hours at (855) 859-2056 (domestic calls) or (404) 537-3406 (international calls) and entering passcode 75749093. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at http://ir.amriglobal.com. About AMRI Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals (FC). For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal). Forward-looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, all of the estimates under "Financial Outlook" and statements regarding, among other things, the performance of the Company's previously acquired businesses, the strength of the Company's commercial operations and prospects, projections regarding future revenues and financial performance, and the Company's momentum and long-term growth. The words "outlook", "guidance", "anticipates", "believes", "expects", "may", "plans", "predicts", "will", "potential", "goal" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. The Company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the Company may not be able to predict and may not be within the Company's control. Factors that could cause such differences include, but are not limited to, changes in customers' spending and demand and the trends in pharmaceutical and biotechnology companies' outsourcing of manufacturing services and research and development; the Company's ability to provide quality and timely services and to compete with other companies providing similar services; the Company's ability to comply with strict regulatory requirements; the Company's ability to successfully integrate past and future acquisitions and to realize the expected benefits of each; disruptions in the Company's ability to source raw materials; a change in the Company's relationships with its largest customers; the Company's ability to service its indebtedness; the Company's ability to protect its technology and proprietary information and the confidential information of its customers; the Company's ability to develop products of commercial value under its collaboration arrangements; the risk of patent infringement and other litigation; as well as those risks discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission (SEC) on March 16, 2017, subsequent Quarterly Reports filed with the SEC and the Company's other SEC filings. The financial guidance offered by senior management with respect to 2017 represents a point-in-time estimate and is based on information as of the date of this press release. Senior management has made numerous assumptions in providing this guidance which, while believed to be reasonable, may not prove to be accurate. Numerous factors, including those noted above, may cause actual results to differ materially from the guidance provided. The Company expressly disclaims any current intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements contained in this press release. Non-GAAP Financial Measures To supplement our financial results prepared in accordance with U.S. GAAP, we have presented non-GAAP measures of contract gross profit, contract gross margin, gross profit, gross margin, SG&A, net income, and earnings per diluted share, adjusted to exclude certain charges (and gains when applicable) that relate to specific events or transactions, such as impairment charges, restructuring charges, executive transition costs, business acquisition costs, realized and unrealized gains and losses on foreign currency transactions related to business acquisitions, and ERP implementation costs. Management typically excludes these amounts when evaluating our operating performance and believes that the resulting non-GAAP measures provide investors with a consistent basis for comparison across periods and, therefore, are useful to investors in assessing our operating performance. Our U.S. GAAP measures are also adjusted to exclude certain non-cash charges (and gains when applicable) such as non-cash debt interest and amortization charges, share-based compensation expense, acquisition accounting inventory adjustments, and acquisition accounting depreciation and amortization for the periods presented for 2017 and 2016. Management typically excludes the amounts described above when evaluating our operating performance and believes that the resulting non-GAAP measures are useful to investors in assessing our operating performance. We have also presented the non-GAAP measure of adjusted EBITDA, which in addition to the items excluded above, further excludes the impact of interest income and expense, depreciation and amortization expense, and income tax expense or benefit. We believe presentation of our non-GAAP measures enhances an overall understanding of our historical financial performance because we believe these measures are an indication of the performance of our base business. Management uses these non-GAAP measures as a basis for evaluating our financial performance as well as for budgeting and forecasting of future periods. For these reasons, we believe they can be useful to investors. The presentation of this additional information should not be considered in isolation or as a substitute for the related GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are set forth in Tables 1-3. A reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures has been included in Table 4. A reconciliation of organic revenue financial measures to the most directly comparable GAAP financial measures has been included in Table 5. Table 1: Reconciliation of three months ended March 31, 2017 and 2016 contract gross profit and contract gross margin to the non-GAAP financial measures of contract gross profit and non-GAAP contract gross margin. Table 2: Reconciliation of select financial measures to non-GAAP financial measures for the three months ended March 31, 2017 and 2016: Table 3: Reconciliation of the three months ended March 31, 2017 and 2016 net loss to the non-GAAP financial measure of adjusted EBITDA: Table 4:  Reconciliation of forward-looking GAAP financial measures to forward looking non-GAAP financial measures: When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis as that would require estimates for various reconciling items that would be difficult to predict with reasonable accuracy.  For example, it is difficult for the Company to anticipate the need for, or magnitude of, any presently unforeseen one-time restructuring expense or business acquisition costs.  As a result, the Company has prepared the below reconciliation using estimates of reconciling items that are currently expected to be excluded from the non-GAAP financial measures in future periods.  The Company is unable to include all reconciling items at this time without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to variability, complexity and limited visibility to events or conditions in future periods. Table 5: Reconciliation of non-GAAP organic revenue for the three months ended March 31, 2017 and 2016: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-announces-first-quarter-2017-results-300453724.html


Amin R.,Chemical Development | Chen J.-X.,Chemical Development | Cotterill I.C.,Fermentation and Biotransformations | Emrich D.,Chemical Development | And 9 more authors.
Organic Process Research and Development | Year: 2013

A practical synthesis targeting the C16-C20 segment of the endogenous metabolite Resolvin E1 (RvE1) is described. The original route was revised to avoid the use of source-constrained raw materials and chemistries that were problematic on larger scale. The revised route utilizes commercially available (E)-1-chloropent-1-en-3-one as the key raw material to replace (S)-glycidol. The (E)-vinyl iodide functionality was installed by an addition/elimination sequence to prepare the segment required for a subsequent Sonogashira coupling. The chiral secondary hydroxyl group at C18 was established by Corey-Bakshi-Shibata (CBS) reduction followed by lipase-catalyzed acetylation to achieve chiral purity in excess of 98% ee. The revised route offered a viable multikilogram process to support early clinical production of this pro-resolution therapeutic agent. © 2013 American Chemical Society.


Deshpande P.P.,Chemical Development | Singh J.,Process Research and Development | Pullockaran A.,Process Research and Development | Kissick T.,Process Research and Development | And 25 more authors.
Organic Process Research and Development | Year: 2012

A practical synthesis of the SGLT-2 inhibitor β-C-aryl-d-glucoside (1) has been developed. The route employed 2,3,4,6-tetra-O-trimethlysilyl-d- glucano-1,5-lactone as the key chiral building block, prepared efficiently from the commercially available, inexpensive raw materials, d-gluconolactone and trimethylsilyl chloride. The salient step in the synthesis is the Lewis acid-mediated stereoselective reduction of a methyl C-aryl peracetylated glycoside using a silyl hydride to set the stereochemistry of the crucial anomeric chiral center. Several novel cocrystalline complexes of 1 with l-phenylalanine and l-proline were discovered. Single-crystal structures of these complexes and several synthetic intermediates have been determined. The l-phenylalanine complex was developed and used to purify and isolate the API. All steps were implemented at multikilogram scale. © 2012 American Chemical Society.


News Article | November 16, 2016
Site: www.newsmaker.com.au

Notes: Sales, means the sales volume of Cetearyl Alcohol Revenue, means the sales value of Cetearyl Alcohol This report studies sales (consumption) of Cetearyl Alcohol in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering KLK OLEO VVF L.L.C Joshi Group Dr. Straetmans HallStar Company BASF Chemyunion Lubrizol Croda SEPPIC Shanghai Saifu Chemical Development Ashland Inc Lonza Group INOLEX Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Cetearyl Alcohol in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Cetearyl Alcohol in each application, can be divided into Application 1 Application 2 Application 3 Global Cetearyl Alcohol Sales Market Report 2016 1 Cetearyl Alcohol Overview 1.1 Product Overview and Scope of Cetearyl Alcohol 1.2 Classification of Cetearyl Alcohol 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Cetearyl Alcohol 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Cetearyl Alcohol Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Cetearyl Alcohol (2011-2021) 1.5.1 Global Cetearyl Alcohol Sales and Growth Rate (2011-2021) 1.5.2 Global Cetearyl Alcohol Revenue and Growth Rate (2011-2021) 2 Global Cetearyl Alcohol Competition by Manufacturers, Type and Application 2.1 Global Cetearyl Alcohol Market Competition by Manufacturers 2.1.1 Global Cetearyl Alcohol Sales and Market Share of Key Manufacturers (2011-2016) 2.1.2 Global Cetearyl Alcohol Revenue and Share by Manufacturers (2011-2016) 2.2 Global Cetearyl Alcohol (Volume and Value) by Type 2.2.1 Global Cetearyl Alcohol Sales and Market Share by Type (2011-2016) 2.2.2 Global Cetearyl Alcohol Revenue and Market Share by Type (2011-2016) 2.3 Global Cetearyl Alcohol (Volume and Value) by Regions 2.3.1 Global Cetearyl Alcohol Sales and Market Share by Regions (2011-2016) 2.3.2 Global Cetearyl Alcohol Revenue and Market Share by Regions (2011-2016) 2.4 Global Cetearyl Alcohol (Volume) by Application Figure Picture of Cetearyl Alcohol Table Classification of Cetearyl Alcohol Figure Global Sales Market Share of Cetearyl Alcohol by Type in 2015 Figure Type I Picture Figure Type II Picture Table Applications of Cetearyl Alcohol Figure Global Sales Market Share of Cetearyl Alcohol by Application in 2015 Figure Application 1 Examples Figure Application 2 Examples Figure United States Cetearyl Alcohol Revenue and Growth Rate (2011-2021) Figure China Cetearyl Alcohol Revenue and Growth Rate (2011-2021) Figure Europe Cetearyl Alcohol Revenue and Growth Rate (2011-2021) Figure Japan Cetearyl Alcohol Revenue and Growth Rate (2011-2021) Figure Global Cetearyl Alcohol Sales and Growth Rate (2011-2021) Figure Global Cetearyl Alcohol Revenue and Growth Rate (2011-2021) Table Global Cetearyl Alcohol Sales of Key Manufacturers (2011-2016) Table Global Cetearyl Alcohol Sales Share by Manufacturers (2011-2016) Figure 2015 Cetearyl Alcohol Sales Share by Manufacturers Figure 2016 Cetearyl Alcohol Sales Share by Manufacturers Table Global Cetearyl Alcohol Revenue by Manufacturers (2011-2016) Table Global Cetearyl Alcohol Revenue Share by Manufacturers (2011-2016) Table 2015 Global Cetearyl Alcohol Revenue Share by Manufacturers Table 2016 Global Cetearyl Alcohol Revenue Share by Manufacturers Table Global Cetearyl Alcohol Sales and Market Share by Type (2011-2016) Table Global Cetearyl Alcohol Sales Share by Type (2011-2016) Figure Sales Market Share of Cetearyl Alcohol by Type (2011-2016) Figure Global Cetearyl Alcohol Sales Growth Rate by Type (2011-2016) Table Global Cetearyl Alcohol Revenue and Market Share by Type (2011-2016) FOR ANY QUERY, REACH US @    Cetearyl Alcohol Sales Global Market Research Report 2016


Mortensen M.A.,Chemical Development | Guo C.,Discovery RandD | Reynolds N.T.,Chemical Development | Wang L.,Chemical Development | And 8 more authors.
Organic Process Research and Development | Year: 2012

Process development and production of a novel tubulin inhibitor are described. The desired API was obtained through selective iodination of the 12′ position of vinblastine and subsequent thiomethylation. Most of the impurities were identified, and process parameters were adjusted to control such impurities. The optimized process was scaled up under cGMP conditions to afford 230 g of the desired API. © 2012 American Chemical Society.


Guz N.R.,Exelixis Inc. | Leuser H.,Chemical Development | Goldman E.,Exelixis Inc.
Organic Process Research and Development | Year: 2013

Route scouting, process development, and multikilogram syntheses of an IGF-1R/Src/Bcr-Abl inihibitor are reported. Key aspects of the developed route are a regioselective [3 + 2] isoxazole formation on a pyrimidine core and a selective SNAr addition of an aryl amine to a symmetrical dichloro substituted pyrimidine. The route contains six synthetic steps and was demonstrated twice on scale, delivering 4.6 and 11.2 kg (25% and 16% overall yield), for Phase I clinical studies. © 2013 American Chemical Society.


Zhu D.,Scripps Research Institute | Yang G.,Scripps Research Institute | He J.,Scripps Research Institute | Chu L.,Scripps Research Institute | And 5 more authors.
Angewandte Chemie - International Edition | Year: 2015

2,4,6-Trimethoxypyridine is identified as an efficient ligand for promoting a Pd-catalyzed ortho-C-H amination of both benzamides and triflyl-protected benzylamines. This finding provides guidance for the development of ligands that can improve or enable PdII-catalyzed Csp2-H activation reactions directed by weakly coordinating functional groups. © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Loading Chemical Development collaborators
Loading Chemical Development collaborators